Summary

The North America calcineurin inhibitors market is expected to reach USD 7.14 billion by 2032 from USD 3.12 billion in 2024, growing with a CAGR of 10.9% in the forecast period of 2024 to 2032.
Market Segmentation:
North America Calcineurin Inhibitors Market, By Drugs (Tacrolimus, Cyclosporine, Pimecrolimus, Voclosporin, and Others), Route of Administeration (Oral, Topical, Parenteral, and Others), Drug type (Branded and Generic), Application (Postoperative Immunosuppression, Atopic Dermatitis, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, and Others), End user (Hospitals, Specialty Clinics, Home Healthcare, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, and Mexico) - Industry Trends And Forecast To 2032

Overview of North America Calcineurin Inhibitors Market Dynamics:

Driver
• Rising Prevalence Of Autoimmune Diseases
Restraint

• Limited Efficacy For Long-Term Use Of Calcineurin Inhibitors
Opportunity

• Growing Demand For Personalized Medicine

Market Players:

The key market players operating in the North America calcineurin inhibitors market are listed below:

• Astellas Pharma US, Inc.
• Lupin
• Viatris Inc
• Glenmark Pharmaceuticals Inc.
• LEO Pharma Inc.
• Bausch Health Companies Inc.
• AbbVie Inc.
• SANDOZ
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd
• Apotex Inc.
• Sun Pharmaceutical Industries Ltd.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF THE NORTH AMERICA CALCINEURIN INHIBITORS MARKET 24
1.4 CURRENCY AND PRICING 26
1.5 LIMITATIONS 26
1.6 MARKETS COVERED 26
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 DBMR TRIPOD DATA VALIDATION MODEL 33
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.6 MULTIVARIATE MODELLING 37
2.7 DBMR MARKET POSITION GRID 38
2.8 VENDOR SHARE ANALYSIS 39
2.9 SECONDARY SOURCES 40
2.10 ASSUMPTIONS 40
3 EXECUTIVE SUMMARY 41
4 PREMIUM INSIGHTS 46
4.1 PORTER’S FIVE FORCES 47
4.2 PESTEL ANALYSIS 48
5 APAC DEPRESSION SCREENING MARKET: REGULATIONS 49
5.1 REGULATORY AUTHORITIES IN NORTH AMERICA. 49
5.1.1 U.S. FOOD AND DRUG ADMINISTRATION (FDA) 49
5.1.2 HEALTH CANADA 50
5.1.3 FEDERAL COMMISSION FOR THE PROTECTION AGAINST SANITARY RISKS (COFEPRIS) - MEXICO 50
5.2 REGULATORY AUTHORITIES IN EUROPE. 51
5.2.1 GERMANY: 51
5.2.2 UNITED KINGDOM: 51
5.2.3 FRANCE: 51
5.2.4 ITALY: 51
5.2.5 SPAIN: 51
5.3 REGULATORY AUTHORITIES IN ASIA-PACIFIC. 52
5.3.1 JAPAN: 52
5.3.2 CHINA: 52
5.3.3 INDIA: 52
5.3.4 SOUTH KOREA: 52
5.3.5 AUSTRALIA: 53
5.4 REGULATORY AUTHORITIES IN MIDDLE EAST AND AFRICA. 53
5.4.1 SAUDI ARABIA: 53
5.4.2 UNITED ARAB EMIRATES (UAE): 53
5.4.3 EGYPT: 53
5.4.4 SOUTH AFRICA: 53
5.5 REGULATORY AUTHORITIES IN SOUTH AMERICA. 54
5.5.1 BRAZIL: 54
5.5.2 ARGENTINA: 54
5.5.3 COLOMBIA: 54
5.5.4 CHILE: 54
6 MARKET OVERVIEW 56
6.1 DRIVERS 58
6.1.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES 58
6.1.2 INCREASING TRANSPLANTATION PROCEDURES 58
6.1.3 ADVANCEMENTS IN MEDICAL TECHNOLOGY 59
6.1.4 GOVERNMENT SUPPORT & FUNDING FOR TRANSPLANTS 60
6.2 RESTRAINTS 61
6.2.1 LIMITED EFFICACY FOR LONG-TERM USE OF CALCINEURIN INHIBITORS. 61
6.2.2 AVAILABILITY OF ALTERNATIVE IMMUNOSUPPRESSIVE THERAPIES. 61
6.3 OPPORTUNITIES 62
6.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE 62
6.3.2 GROWING GERIATRIC POPULATION 63
6.3.3 ADVANCEMENTS IN DRUG DELIVERY 63
6.4 CHALLENGES 64
6.4.1 COMPLEX DOSING AND MONITORING 64
6.4.2 HIGH COSTS 64
7 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DRUGS 65
7.1 OVERVIEW 66
7.2 TACROLIMUS 69
7.2.1 GENERIC 69
7.2.2 BRANDED 70
7.2.2.1 PROGRAF 70
7.2.2.2 ASTAGRAF XL 70
7.2.2.3 ENVARSUS XR 70
7.2.2.4 OTHER 70
7.2.2.4.1 CAPSULES 70
7.2.2.4.2 TABLETS 70
7.2.2.4.3 INJECTIONS 71
7.2.2.4.4 GRANULES FOR ORAL SUSPENSION 71
7.2.2.4.4.1 1 MG 71
7.2.2.4.4.2 0.5 MG 71
7.2.2.4.4.3 5 MG 71
7.2.2.4.4.4 OTHERS 71
7.2.2.4.4.5 ADULT 72
7.2.2.4.4.6 GERIATRIC 72
7.2.2.4.4.7 PEDIATRIC 72
7.3 CYCLOSPORINE 72
7.3.1 GENERIC 72
7.3.2 BRANDED 73
7.3.2.1 NEORAL 73
7.3.2.2 SANDIMMUNE 73
7.3.2.3 GENGRAF 73
7.3.2.4 OTHERS 73
7.3.2.4.1 CAPSULES 74
7.3.2.4.2 ORAL SOLUTION 74
7.3.2.4.3 INJECTION 74
7.3.2.4.4 OTHERS 74
7.3.2.4.4.1 100 MG 74
7.3.2.4.4.2 25 MG 74
7.3.2.4.4.3 50 MG 74
7.3.2.4.4.4 OTHERS 74
7.3.2.4.4.5 ADULT 75
7.3.2.4.4.6 PEDIATRIC 75
7.3.2.4.4.7 GERIATRIC 75
7.4 PIMECROLIMUS (TOPICAL CREAM) 75
7.4.1 GENERIC 75
7.4.2 BRANDED 75
7.4.2.1 ADULT 76
7.4.2.2 GERIATRIC 76
7.4.2.3 PEDIATRIC 76
7.5 VOCLOSPORIN (ORAL CAPSULE) 76
7.6 OTHERS 77
7.6.1 GENERIC 77
7.6.2 BRANDED 77
8 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE 78
8.1 OVERVIEW 79
8.2 GENERIC 82
8.2.1 POSTOPERATIVE IMMUNOSUPPRESSION 82
8.2.2 ATOPIC DERMATITIS 82
8.2.3 ULCERATIVE COLITIS 82
8.2.4 PSORIASIS 83
8.2.5 KERATOCONJUNCTIVITIS 83
8.2.6 OTHERS 83
8.3 BRANDED 83
8.3.1 POSTOPERATIVE IMMUNOSUPPRESSION 84
8.3.2 ATOPIC DERMATITIS 84
8.3.3 ULCERATIVE COLITIS 84
8.3.4 PSORIASIS 84
8.3.5 KERATOCONJUNCTIVITIS 84
8.3.6 OTHERS 84
9 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY APPLICATION 85
9.1 OVERVIEW 86
9.2 POSTOPERATIVE IMMUNOSUPPRESSION 89
9.3 ATOPIC DERMATITIS 89
9.4 ULCERATIVE COLITIS 90
9.5 PSORIASIS 90
9.6 KERATOCONJUNCTIVITIS 91
9.7 OTHERS 91
10 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION 92
10.1 OVERVIEW 93
10.2 ORAL 96
10.2.1 CAPSULE 96
10.2.2 TABLET 96
10.2.3 SOLUTION 96
10.3 TOPICAL 97
10.4 PARENTERAL 97
10.5 OTHERS 98
11 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY END USER 99
11.1 OVERVIEW 100
11.2 HOSPITALS 103
11.3 SPECIALTY CLINICS 104
11.4 HOME HEALTHCARE 104
11.5 ACADEMIC AND RESEARCH INSTITUTES 105
11.6 OTHERS 105
12 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL 106
12.1 OVERVIEW 107
12.2 HOSPITAL PHARMACY 110
12.3 RETAIL PHARMACY 110
12.4 ONLINE PHARMACY 111
12.5 OTHERS 111
13 NORTH AMERICA CALCINEURIN INHIBITOR MARKET, BY REGION 112
13.1 NORTH AMERICA 114
14 NORTH AMERICA CALCINEURIN INHIBITORS MARKET, COMPANY LANDSCAPE 147
14.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
15 SWOT ANALYSIS 148
16 COMPANY PROFILES 149
16.1 ASTELLAS PHARMA US, INC. 149
16.1.1 COMPANY SNAPSHOT 149
16.1.2 REVENUE ANALYSIS 150
16.1.3 COMPANY SHARE ANALYSIS 150
16.1.4 PRODUCT PORTFOLIO 151
16.1.5 RECENT DEVELOPMENT 151
16.2 CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD 152
16.2.1 COMPANY SNAPSHOT 152
16.2.2 REVENUE ANALYSIS 152
16.2.3 COMPANY SHARE ANALYSIS 153
16.2.4 PRODUCT PORTFOLIO 153
16.2.5 RECENT DEVELOPMENT 153
16.3 LUPIN 154
16.3.1 COMPANY SNAPSHOT 154
16.3.2 REVENUE ANALYSIS 154
16.3.3 COMPANY SHARE ANALYSIS 155
16.3.4 PRODUCT PORTFOLIO 155
16.3.5 RECENT DEVELOPMENT 155
16.4 HUADONG MEDICINE CO.,LTD 156
16.4.1 COMPANY SNAPSHOT 156
16.4.2 REVENUE ANALYSIS 156
16.4.3 COMPANY SHARE ANALYSIS 157
16.4.4 PRODUCT PORTFOLIO 157
16.4.5 RECENT DEVELOPMENT 157
16.5 VIATRIS INC. 158
16.5.1 COMPANY SNAPSHOT 158
16.5.2 REVENUE ANALYSIS 158
16.5.3 COMPANY SHARE ANALYSIS 159
16.5.4 PRODUCT PORTFOLIO 159
16.5.5 RECENT DEVELOPMENT 159
16.6 APOTEX INC. 160
16.6.1 COMPANY SNAPSHOT 160
16.6.2 PRODUCT PORTFOLIO 160
16.6.3 RECENT DEVELOPMENT 160
16.7 ABBVIE INC 161
16.7.1 COMPANY SNAPSHOT 161
16.7.2 REVENUE ANALYSIS 161
16.7.3 PRODUCT PORTFOLIO 162
16.7.4 RECENT DEVELOPMENT 162
16.8 ACCORD HEALTHCARE US. 163
16.8.1 COMPANY SNAPSHOT 163
16.8.2 PRODUCT PORTFOLIO 163
16.8.3 RECENT DEVELOPMENT 163
16.9 ACTIZAPHARMA 164
16.9.1 COMPANY SNAPSHOT 164
16.9.2 PRODUCT PORTFOLIO 164
16.9.3 RECENT DEVELOPMENT 165
16.10 ADVACARE PHARMA 166
16.10.1 COMPANY SNAPSHOT 166
16.10.2 PRODUCT PORTFOLIO 166
16.10.3 RECENT DEVELOPMENT 166
16.11 BIOCON 167
16.11.1 COMPANY SNAPSHOT 167
16.11.2 REVENUE ANALYSIS 167
16.11.3 PRODUCT PORTFOLIO 168
16.11.4 RECENT DEVELOPMENT 168
16.12 BAUSCH HEALTH COMPANIES INC. 169
16.12.1 COMPANY SNAPSHOT 169
16.12.2 REVENUE ANALYSIS 169
16.12.3 PRODUCT PORTFOLIO 170
16.12.4 RECENT DEVELOPMENT 170
16.13 CONCORD BIOTECH 171
16.13.1 COMPANY SNAPSHOT 171
16.13.2 REVENUE ANALYSIS 171
16.13.3 PRODUCT PORTFOLIO 172
16.13.4 RECENT DEVELOPMENT 172
16.14 DR. REDDY’S LABORATORIES 173
16.14.1 COMPANY SNAPSHOT 173
16.14.2 REVENUE ANALYSIS 173
16.14.3 PRODUCT PORTFOLIO 174
16.14.4 RECENT DEVELOPMENT 174
16.15 GLENMARK PHARMACEUTICALS INC 175
16.15.1 COMPANY SNAPSHOT 175
16.15.2 REVENUE ANALYSIS 175
16.15.3 PRODUCT PORTFOLIO 176
16.15.4 RECENT DEVELOPMENT 176
16.16 LEO PHARMA INC. 177
16.16.1 COMPANY SNAPSHOT 177
16.16.2 PRODUCT PORTFOLIO 177
16.16.3 RECENT DEVELOPMENT 177
16.17 LIPELLA PHARMACEUTICALS, INC. 178
16.17.1 COMPANY SNAPSHOT 178
16.17.2 REVENUE ANALYSIS 178
16.17.3 PRODUCT PORTFOLIO 179
16.17.4 RECENT DEVELOPMENT 179
16.18 NOVARTIS AG 180
16.18.1 COMPANY SNAPSHOT 180
16.18.2 REVENUE ANALYSIS 180
16.18.3 PRODUCT PORTFOLIO 181
16.18.4 RECENT DEVELOPMENT 181
16.19 NOVALIQ GMBH 182
16.19.1 COMPANY SNAPSHOT 182
16.19.2 PRODUCT PORTFOLIO 182
16.19.3 RECENT DEVELOPMENT 182
16.20 PANACEA BIOTEC 183
16.20.1 COMPANY SNAPSHOT 183
16.20.2 REVENUE ANALYSIS 183
16.20.3 PRODUCT PORTFOLIO 184
16.20.4 RECENT DEVELOPMENT 186
16.21 PADAGIS 187
16.21.1 COMPANY SNAPSHOT 187
16.21.2 PRODUCT PORTFOLIO 187
16.21.3 RECENT DEVELOPMENT 187
16.22 RPG LIFE SCIENCES LIMITED 188
16.22.1 COMPANY SNAPSHOT 188
16.22.2 REVENUE ANALYSIS 188
16.22.3 PRODUCT PORTFOLIO 189
16.22.4 RECENT DEVELOPMENT 189
16.23 VELOXIS PHARMACEUTICALS, INC. 190
16.23.1 COMPANY SNAPSHOT 190
16.23.2 REVENUE ANALYSIS 190
16.23.3 PRODUCT PORTFOLIO 190
16.23.4 RECENT DEVELOPMENT 190
16.24 ZHAOKE OPHTHALMOLOGY LIMITED 191
16.24.1 COMPANY SNAPSHOT 191
16.24.2 REVENUE ANALYSIS 191
16.24.3 PRODUCT PORTFOLIO 192
16.24.4 RECENT DEVELOPMENT 192
16.25 ZAMBON COMPANY S.P.A. 193
16.25.1 COMPANY SNAPSHOT 193
16.25.2 PRODUCT PORTFOLIO 193
16.25.3 RECENT DEVELOPMENT 194
17 QUESTIONNAIRE 195
18 RELATED REPORTS 198